Evidence map›Paper›PMID 41792746›Full record

ArticleJournal of nanobiotechnology2026

A stable two-component cationic liposome platform for mRNA delivery induces CD8

Gabriel Kristian Pedersen, Reham Sabah Alhakeem, Ahmad Tami, Dennis Christensen, Zahra Shabanian, Rune Fledelius Jensen, Katharina Wørzner, Signe Tandrup Schmidt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriel Kristian PedersenDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Reham Sabah AlhakeemDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Ahmad TamiDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Dennis ChristensenDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Zahra ShabanianDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Rune Fledelius JensenDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Katharina WørznerDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark.
Signe Tandrup SchmidtDepartment of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark. sxs@ssi.dk.ORCID http://orcid.org/0000-0002-5631-571X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mRNA-LNP-based SARS-CoV-2 vaccines were a breakthrough for the technology; however, their production requires specialized equipment, and the complex formulation involving four distinct lipid classes imposes stringent requirements on both characterization and quality control. We tested a cationic adjuvant formulation containing a simple two-component liposome formulation based on dimethyldioctadecylammonium bromide and monomycoloyl glycerol-1 (CAF

Indexed as

CD8-Positive T-LymphocytesLiposomesLymphomaRNA, MessengerAdjuvants, ImmunologicAnimalsCancer VaccinesCationsCOVID-19 VaccinesDisease Models, AnimalFemaleMiceMice, Inbred C57BLQuaternary Ammonium CompoundsAdjuvants, ImmunologicCancer VaccinesCationsCOVID-19 VaccinesdimethyldioctadecylammoniumLiposomesQuaternary Ammonium CompoundsRNA, MessengerCancer vaccineCationic liposomeCytotoxic T cellMRNA

Identifiers

PMID41792746
PMCPMC13081595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.